

# Preclinical study for the development of MRI contrast agent of innovative artificial melanin

BL Melanis Co., Ltd.



ONCOLOGY	Non-Clinical
Product Type	MRI contrast agent
Indication	Liver disease, Liver cancer, Kidney cancer, Chronic fibrosis disease
Target	Liver, Kidney
MoA(Mechanism of Action)	-
Competitiveness	<ol style="list-style-type: none"> <li>1. More than 10 times superior contrast medium compared to gadolinium contrast agent. (Gadovist 100 <math>\mu\text{mol/kg}</math> vs ML-101 10 <math>\mu\text{mol/kg}</math>)</li> <li>2. Compared to the approved contrast agents, the development period is shorter, enabling rapid market entry and early technology export</li> <li>3. Artificially produced melanin is a material that is useful not only in diagnosis but also in medicine and material engineering, and research is being actively conducted to utilize it in various fields. It is possible to develop and expand new indications by securing technology and intellectual property rights for artificial melanin production for the first time in Korea.</li> <li>4. It will be the first case of successfully overcoming the problems of the existing MRI contrast agents with domestic technology and developing a new drug.</li> </ol>
Development Stage	Non-Clinical
Route of Administration	i.v.